Anisimov VN
GLP-1 medications are compatible with most postpartum medications, including common antidepressants, thyroid medications, and prenatal vitamins
Your impatience is not worth your health
Research on GLP-1 medications such as Zepbound and Wegovy shows that reporting outcomes as percentages or average ranges can help standardize results across individuals
With all four core TRIUMPH trials now complete TRIUMPH-4 (December 2025, 28.7% weight loss), TRIUMPH-1 (May 2026, 28.3% in 2,339 patients), TRIUMPH-2 (July 2026, obesity + diabetes), and TRIUMPH-3 (July 2026, obesity + cardiovascular disease) plus TRANSCEND-T2D-1 (June 2026, the first diabetes-specific Phase 3 readout), this investigational medication now has the full data package Eli Lilly says it needs for regulatory submission